Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/205577
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Mascaraque, Marta | - |
dc.contributor.author | Delgado-Wicke, Pablo | - |
dc.contributor.author | Nuevo-Tapioles, Cristina | - |
dc.contributor.author | Gracia-Cazaña, Tamara | - |
dc.contributor.author | Abarca-Lachen, Edgar | - |
dc.contributor.author | González, Salvador | - |
dc.contributor.author | Cuezva, José M. | - |
dc.contributor.author | Gilaberte, Yolanda | - |
dc.contributor.author | Juarranz, Ángeles | - |
dc.date.accessioned | 2020-03-27T13:24:10Z | - |
dc.date.available | 2020-03-27T13:24:10Z | - |
dc.date.issued | 2020-03-13 | - |
dc.identifier.citation | Cancers 12(3): 668 (2020) | - |
dc.identifier.uri | http://hdl.handle.net/10261/205577 | - |
dc.description | © 2020 by the authors. | - |
dc.description.abstract | Photodynamic Therapy (PDT) with methyl-aminolevulinate (MAL-PDT) is being used for the treatment of Basal Cell Carcinoma (BCC), although resistant cells may appear. Normal differentiated cells depend primarily on mitochondrial oxidative phosphorylation (OXPHOS) to generate energy, but cancer cells switch this metabolism to aerobic glycolysis (Warburg effect), influencing the response to therapies. We have analyzed the expression of metabolic markers (β-F1-ATPase/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) ratio, pyruvate kinase M2 (PKM2), oxygen consume ratio, and lactate extracellular production) in the resistance to PDT of mouse BCC cell lines (named ASZ and CSZ, heterozygous for ptch1). We have also evaluated the ability of metformin (Metf), an antidiabetic type II compound that acts through inhibition of the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway to sensitize resistant cells to PDT. The results obtained indicated that resistant cells showed an aerobic glycolysis metabolism. The treatment with Metf induced arrest in the G0/G1 phase and a reduction in the lactate extracellular production in all cell lines. The addition of Metf to MAL-PDT improved the cytotoxic effect on parental and resistant cells, which was not dependent on the PS protoporphyrin IX (PpIX) production. After Metf + MAL-PDT treatment, activation of pAMPK was detected, suppressing the mTOR pathway in most of the cells. Enhanced PDT-response with Metf was also observed in ASZ tumors. In conclusion, Metf increased the response to MAL-PDT in murine BCC cells resistant to PDT with aerobic glycolysis. | - |
dc.description.sponsorship | This research was funded by Spanish grants from Instituto de Salud Carlos III MINECO and Feder Funds (FIS PI15/00974 and PI18/00708) and Ministerio de Ciencia, Innovación y Universidades (SAF2016-75916-R). | - |
dc.language.iso | eng | - |
dc.publisher | Multidisciplinary Digital Publishing Institute | - |
dc.relation | info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2016-75916-R | - |
dc.relation.isversionof | Publisher's version | - |
dc.rights | openAccess | - |
dc.subject | Basal cell carcinoma | - |
dc.subject | Photodynamic therapy | - |
dc.subject | Resistance | - |
dc.subject | Metabolic markers | - |
dc.subject | Metformin | - |
dc.title | Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells | - |
dc.type | artículo | - |
dc.identifier.doi | 10.3390/cancers12030668 | - |
dc.description.peerreviewed | Peer reviewed | - |
dc.relation.publisherversion | https://doi.org/10.3390/cancers12030668 | - |
dc.identifier.e-issn | 2072-6694 | - |
dc.date.updated | 2020-03-27T13:24:11Z | - |
dc.rights.license | http://creativecommons.org/licenses/by/4.0/ | - |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003329 | es_ES |
dc.identifier.pmid | 32183017 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | artículo | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
Aparece en las colecciones: | (CBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Metformin_Mascaraque_Art2020.pdf | 4,14 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 01-abr-2024
SCOPUSTM
Citations
13
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
11
checked on 25-feb-2024
Page view(s)
108
checked on 23-abr-2024
Download(s)
99
checked on 23-abr-2024